PURE Announces Distribution Agreement with Brenntag Specialties, Inc. -Distribution Rights of SILVÉRION® 2400 for Personal Care Products

SAN DIEGO, CA (December 02, 2013) – PURE Bioscience, Inc. (OTCQB: PURE), creator of the patented silver dihydrogen citrate (SDC) antimicrobial, today announced it has entered into a three-year distribution agreement with Brenntag Specialties, Inc. (“Brenntag”). The non-exclusive agreement provides Brenntag the worldwide rights to distribute PURE’s unique and proprietary SDC-based antimicrobial SILVÉRION® 2400 as an active ingredient or preservative for use in personal care products.

The distribution agreement formalizes a two-year relationship between PURE and Brenntag, in which Brenntag purchases SILVÉRION 2400 and distributes to personal care consumer products companies for their use as an antimicrobial ingredient. SILVÉRION is PURE’s trademark and is positioned in the personal care products market as a natural antimicrobial ingredient that replaces preservatives including parabens, formaldehyde donors and isothiazolinones as well as providing a natural active biocide effective at low concentrations.

The Company stated that the distribution agreement with Brenntag is consistent with its new business strategy to out-license its antimicrobial SDC-technology in non-core operating activities for commercialization with industry and market leading companies.

About SILVÉRION 2400

SILVÉRION® 2400 delivers the powerful antimicrobial activity of SDC as a versatile, broad-spectrum antimicrobial to the consumer products market. SILVÉRION® 2400 provides an easy to use solution which can be formulated as an active biocide or preservative in a variety of personal care and deodorant products.

About Brenntag Specialties, Inc.

On September 1, 2007, Brenntag North America embarked on a new strategy that transformed their two specialty companies, Mineral and Pigment Solutions and ChemTech Specialties, into a new organization called Brenntag Specialties, Inc. (BSI). This bold “growth strategy” enables Brenntag to leverage the substantial specialty resources that currently existed within the organization and provides additional long-term value to our customers and the manufacturers we represent. The result of these efforts is a seasoned sales force that will focus on the specialty business. Our technical sales representatives work with chemists as well as research and development professionals to identify market needs. This partnership allows our customers to see the newest products and technology coming to market, and provides direct input into new product development.

Brenntag Specialties offers a broad product portfolio produced by the world's leading specialty manufacturers, and is an offering second to none. Our Sales and Marketing teams are supported by 6 regional customer service centers, 17 warehouses across the US and Canada, technical service, regulatory and analytical laboratories. Our customers will receive the highest quality and service, that which not only meets, but exceeds their expectations.

About PURE Bioscience, Inc.

PURE Bioscience, Inc. is focused on developing and commercializing our proprietary antimicrobial products that provide solutions to the health and environmental challenges of pathogen and hygienic control. Our technology platform is based on patented stabilized ionic silver, and our initial products contain silver dihydrogen citrate, or SDC. SDC is a broad-spectrum, non-toxic antimicrobial agent, which offers 24-hour residual protection and formulates well with other compounds. As a platform technology, SDC is distinguished from existing products in the marketplace because of its superior efficacy, reduced toxicity and the inability of bacteria to form a resistance to it. PURE is headquartered in El Cajon, California (San Diego metropolitan area). Additional information on PURE is available at

Forward-looking Statements

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements inherently involve risks and uncertainties that could cause our actual results to differ materially from the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, the Company’s cash position and liquidity requirements, the Company’s failure to implement or otherwise achieve the benefits of its proposed business initiatives and plans, acceptance of the Company's current and future products and services in the marketplace, the ability of the Company to develop effective new products and receive regulatory approvals of such products, competitive factors, dependence upon third-party vendors, and other risks detailed in the Company's periodic report filings with the Securities and Exchange Commission, including our annual report on Form 10-K filed October 24, 2013. You should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release.

Tom Hemingway
Redwood Investment Group

Terri MacInnis, Director of IR
Bibicoff + MacInnis, Inc.

Company Contact:
Peter C. Wulff, CFO & COO
PURE Bioscience, Inc.
619-596-8600 ext.111